Life Science completes its Phase I milestones and receives a Notice of Award for the Phase II component of its FastTrack SBIR grant titled, “Sirtuin Agonists as Pan Influenza Antivirals” (4R44AI122488-02). Read more
FORGE Life Science enters into a Sponsored Research Agreement with St. Jude Children’s Research Hospital. FORGE will collaborate with Drs. Richard J. Webby and Elena Govorkova to study the effect of FORGE host-targeted antivirals in ferret models of respiratory infection.
FORGE Life Science enters into a Cooperative Research & Development Agreement with the U.S. Army Medical Research Institute of Infectious Disease to test FORGE host-targeted antivirals against Department of Defense priority pathogens such as Marburg virus, Venezuelan equine encephalitis virus, and Lassa virus.
FORGE Life Science President & CEO, Lillian Chiang, is selected to join Springboard Enterprises Health Innovation Hub 2018: Life Sciences Track cohort for women entrepreneurs. Read more
FORGE Life Science completes Milestone 1 in agreement with BioArdis, LLC, securing second tranche of in-kind services investment.
FORGE Life Science announces final close of $6.3 M raised in Series A-1 financing with participation by all founding investors. The funds will progress FORGE’s novel first-in-class host-targeted antivirals towards delivering transformational broad-spectrum treatment modalities to patients in need.
FORGE Life Science President & CEO, Lillian Chiang, presents “Targeting Host-cell Metabolism to Address Multiple Intracellular Pathogens” at the 2017 Chemical and Biological Defense Science & Technology Conference, Long Beach, CA. Read more
FORGE Life Science secures a second in-kind services investment from BioArdis, LLC, expanding FORGE medicinal chemistry and DMPK research resources to include BioDuro, global provider of contract research services.
FORGE Life Science Board of Directors meeting with new external members Richard J. Whitley, Brian Pusch, Steven Holtzman joining Founders Thomas E. Shenk and Lillian W. Chiang on the Board.
FORGE Life Science President & CEO, Lillian Chiang, presents at 9th Annual Biotech Showcase 2017 investor conference in San Francisco, CA.
